½ÉÀå´ë»çÁõÈıºÇÐȸ 2024 7th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS (2ÀÏÂ÷) : 2024-04-27 |
|
½ÉÀå´ë»çÁõÈıºÇÐȸ 2024 7th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS (2ÀÏÂ÷) : 2024-04-27 ±³À°ÁÖÁ¦ : 2024 7th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS (2ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ ´ã´çÀÚ : ±è¼±¿Á À̸ÞÀÏ : apcms@kscms.org ±³À°Á¾·ù : ³»°ú Âü¼®¿¹»óÀÎ : 200¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 140,000¿ø ºñ°í Àü¹®ÀÇ,±³¼ö: ȸ¿ø 120000, ºñȸ¿ø 140000 ÀüÀÓÀÇ,Àü°øÀÇ,±ºÀÇ°ü,°øº¸ÀÇ,¿¬±¸¿ø,°£È£»ç,¿µ¾ç»ç,¾à»ç,±â¾÷ȸ¿ø,±âŸ: 60000
±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 08:30~08:45 Potential Mechanism of SGLT2i in HF À̼ö¿ë(ºÎ»êÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 08:45~09:00 Metabolic Reprogramming of SGLT2i in Isolated Perfusion Hearts ¹ÚÈÆÁØ(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 09:00~09:15 Effects of SGLT2i on Afib and Stroke ÃÖ¿µ(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 09:15~09:30 Efficacy of SGLT2 Inhibitors with Different SGLT1/SGLT2 Selectivity in CV Outcomes ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë ³»ºÐºñ³»°ú) Åä·Ð 04¿ù 27ÀÏ Room 1 09:30~09:50 Discussion ¼Á¸(¼øõÇâÀÇ´ë ½ÉÀå³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 14:40~14:50 (Abstract) Foxm1-Mediated Mitochondrial Function In Cardiomyocytes Protects Cardiac Ischemic Injury Through Suppressing Mkrn1-Dependent LKB1 Ubiquitination Shuai Song(Zhongshan Hospital, Fudan University) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 14:50~15:00 (Abstract) Ketogenic Diet Protects Cardiac Lipid Deposit And Inflammation in Advanced Cardiac Aging in A GIP-dependent Fashion Yasuko K Bando(Mie Univ. Graduate School of Medicine) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 15:00~15:10 (Abstract) Association of lipoprotein(a) with NAFLD and MAFLD °Á¤±Ô(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 15:10~15:20 (Abstract) Effect of Yoga Therapy on Disease Activity, Inflammatory Markers and Heart Rate Variability in Patients with Osteoarthritis Knee Patients Vandana Awasthi(King George) Åä·Ð 04¿ù 27ÀÏ Room 1 15:20~15:30 Discussion ±è´Ù·¡(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 15:40~15:55 Evolving Perspectives: 2022 Updates in Korean Hypertension Guidelines ±èÇзÉ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 15:55~16:10 Digital Therapeutics for Hypertension: Maximizing the Effects of Lifestyle Modification Akihiro Nomura(Kanazawa Univ.) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 16:10~16:25 Evidence and Perspective of Out-of-office Blood Pressure in Japan Satoshi Hoshide(Jichi Medical Univ. School of Medicine) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1 16:25~16:40 Empowering Health: The Vital Role of Patient Education in Managing Hypertension and Cardiometabolic Syndrome in Korea ±èÇöÁø(ÇѾçÀÇ´ë ½ÉÀå³»°ú) Åä·Ð 04¿ù 27ÀÏ Room 1 16:40~17:00 Discussion ¹Ú»ó¹Î(À»ÁöÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 08:30~08:45 Recent Advances in the Pathogenesis of NAFLD ÀÌ¿µ¼±(°í·ÁÀÇ´ë ¼Òȱ⳻°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 08:45~09:00 NAFLD, Diabetes, and CVD ÇÑÀ¯Áø(°è¸íÀÇ´ë ³»ºÐºñ³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 09:00~09:15 NAFLD and Cardiometabolic Syndrome: Exploring the Role of Liver Fibrosis ÀÌÇý¿ø(¿¬¼¼ÀÇ´ë ¼Òȱ⳻°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 09:15~09:30 Targeting Treatment in NAFLD ¹ÚÁ¤È¯(ÇѾçÀÇ´ë ³»ºÐºñ³»°ú) Åä·Ð 04¿ù 27ÀÏ Room 2 09:30~09:50 Discussion À¯¼öÁ¾(¼¿ïÀÇ´ë ¼Òȱ⳻°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 14:40~14:50 (Abstract) Deep Learning Analysis of Ocular Biomarkers for Early Prediction of Cardiometabolic Syndrome Using Optical Coherence Tomography Rifaldy Fajar(Karlstad University) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 14:50~15:00 (Abstract) Eligibility and cost-utility analysis of dapagliflozin in patients with heart failure across the whole spectrum of ejection fraction in South Korea À±Á¾Âù(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 15:00~15:10 (Abstract) Proof Extraction from Medical Guidelines Using Chain of Reasoning for Cardiac Patient Assessment Ubaid Ur Rehman(Kyung Hee University) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 15:10~15:20 (Abstract) Cardiovascular health status of people with elevated lipoprotein(a) identified via a cascade testing program: opportunity for prevention Dick Chi Chan(University of Western Australia) Åä·Ð 04¿ù 27ÀÏ Room 2 15:20~15:30 Discussion ÁÖÇüÁØ(°í·ÁÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 15:40~16:00 Understanding TRL and TG Metabolism and Its Relationship with Cardiovascular Risk ÀÌ»óÇÐ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 16:00~16:20 Remnant Cholesterol and Atherosclerotic Cardiovascular Disease ±è³²ÈÆ(°í·ÁÀÇ´ë ³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 16:20~16:40 TG-lowering Therapy Strategies in the Statin Era Á¶»óÈ£(ÇѸ²ÀÇ´ë ½ÉÀå³»°ú) Åä·Ð 04¿ù 27ÀÏ Room 2 16:40~17:00 Discussion ¹Î¼¼Èñ(¿ï»êÀÇ´ë ³»ºÐºñ³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 17:10~17:20 (Abstract) The adiponectin receptor agonist ALY688 prevents pressure overload-induced heart failure with reduced ejection fraction (HFrEF). Sungji Cho(York University) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 17:20~17:30 (Abstract) Comparative Efficacy of of High-Dose Rosuvastatin and Atorvastatin in Preventing Cystatin C-Oriented Contrast-induced Nephropathy in Statin-naïve Patients with Acute Myocardial Infarction:From the RACCOON study ±èÁöÇý(ÃæºÏÀÇ´ë) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 17:30~17:40 (Abstract) Transcriptomic Analysis Illustrates Unique Metabolic Characteristics Of Activated Cardiac Fibroblasts In Experimental Myocardial Infarction. Zihang Huang(Zhongshan Hospital, Fudan University) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 2 17:40~17:50 (Abstract) Is usage of mobile phones disrupting sleep in Patients with Metabolic Syndrome? A Comparative Study on Artificial Light at night (ALAN) Light Pollution as a Zeitgeber Smriti Rastogi(King George) Åä·Ð 04¿ù 27ÀÏ Room 2 17:40~17:50 Discussion À±Á¾Âù(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 08:30~08:45 Perspective on Diagnostic Methods and Criteria for Obesity ±èº¸¿¬(¼øõÇâÀÇ´ë ³»ºÐºñ³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 08:45~09:00 Obesity Related Cardiometabolic Disorders ±èÇý¹Ì(Áß¾ÓÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 09:00~09:15 Obesity Paradox in Heart Diseases Á¤¹ÌÇâ(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 09:15~09:30 Obesity and Sleep Disorder Alice PS Kong(Hong Kong SAR, China) Åä·Ð 04¿ù 27ÀÏ Room 3 09:30~09:50 Discussion ¼¹ÌÇý(¼øõÇâÀÇ´ë ³»ºÐºñ³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 13:00~13:20 Cardiovascular Complications in Chronic Kidney Disease: Mechanisms and Clinical Implications À§Áø(°¡ÃµÀÇ´ë ½ÉÀå³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 13:20~13:40 Lifestyle Intervention for the Prevention and Treatment of CMS-related Kidney Disease ±Ç¼ÒÀÌ(Áß¾ÓÀÇ´ë ½ÅÀå³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 13:40~14:00 Pharmacological Interventions for CMS and Kidney Disease ¼ÕÇüÀº(Áß¾ÓÀÇ´ë ½ÅÀå³»°ú) Åä·Ð 04¿ù 27ÀÏ Room 3 14:00~14:20 Discussion ¼Àçºó(¼¿ïÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 14:30~14:45 Introduction of Lp(a) Florian Kronenberg(Medical Univ. of Innsbruck) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 14:45~15:00 Genetic Epidemiologic Evidence for Lp(a) Pia R. Kamstrup(Copenhagen Univ. Hospital – Herlev Gentofte) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 15:00~15:15 Current Status and Perspectives of Lp(a) Treatment Stephen J. Nicholls(Monash Health) Åä·Ð 04¿ù 27ÀÏ Room 3 15:15~15:30 Discussion Á¶°æÈÆ(Àü³²ÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 15:40~15:55 Induction of KLF2 by Exercise Activates eNOS to Improve Endothelial Function in Diabetic Mice Yu Huang(City Univ. of Hong Kong) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 15:55~16:10 Roles of CHIP Ubiquitin Ligase in Steatohepatitis ¿ìâÈÆ(¿µ³²ÀÇ´ë ¾à¸®Çб³½Ç) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 16:10~16:25 Atheroslerosis-promoting Effect of Porphyrimonas Gingivalis Infection ¹Ú¿µ¹Ì(ÀÌÈÀÇ´ë ºÐÀÚÀÇÇб³½Ç) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 3 16:25~16:40 Cellular Senescence Promotes Pathogenesis in Cardiovascular-metabolic Diseases Ippei Shimizu (National Cerebral and Cardiovascular Center) Åä·Ð 04¿ù 27ÀÏ Room 3 16:40~17:00 Discussion ÃÖ¿¬Á÷(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1+2 13:00~13:30 Implication of Sarcopenia in Cardiometabolic Health Hidenori Arai (National Center for Geriatrics and Gerontology) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1+2 13:30~14:00 When Being Lean is Not Enough: The Metabolically-unhealthy Normal-weight Phenotype and Cardiometabolic Disease Faidon Magkos (Univ. of Copenhagen) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1+2 14:00~14:30 Cross-sectional Analysis of AMI Patients of Korea and Chinese Xian Wu Cheng (Yanbian Univ. Hospital) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1+2+3 10:00~10:30 Beyond the Myths: The Realities of HyperTG on Cardiovascular Outcomes ÇѽÂȯ(President of the KSCMS & APCMS) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1+2+3 10:30~11:00 Vascular Lipid Metabolism in Atherosclerosis William A. Boisvert(Univ. of Hawaii School of Medicine) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1+2+3 11:00~11:30 Unveiling the Roles of Peroxiredoxins in Cardiovascular Pathologies: A Comprehensive Exploration ¿À±¸ÅÃ(ÀÌÈ¿©´ë »ý¸í°úÇаú) ±³À°½Ã°£ 04¿ù 27ÀÏ Room 1+2+3 11:30~12:00 Should Dyslipidemia Guidelines Be Changed in Statins Era? °í±¤°ï(K Heart Clinic)
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|
Á¦¸ñ |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 894 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 686 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 656 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 775 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 822 , ´ñ±Û¼ö : 0 |